eligibility_summary
Eligibility: Adults ≥18 with NSCLC, urothelial carcinoma, or melanoma, measurable disease (RECIST 1.1), tumor tissue for PD‑L1/CD73/B7‑H3 (NSCLC may use local PD‑L1), adequate organs, expected survival ≥3 mo, contraception and, if applicable, negative pregnancy test. Exclusions: curable local disease, prior PD‑1/PD‑L1/PD‑L2 or similar IO, recent therapy/radiation/surgery or other trial tx, active CNS mets, immunosuppressed autoimmunity, other active cancers, transplant, HCV RNA+ or HIV+, ILD/pneumonitis, major CV/GI disease, recent DVT/thrombolytics, uncontrolled seizures, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT05338580 (withdrawn). Intervention: TJ271 Injection plus pembrolizumab. Drug types/mechanisms: • Pembrolizumab – humanized IgG4 monoclonal antibody (immune checkpoint inhibitor) that blocks PD‑1 on T cells, preventing PD‑L1/PD‑L2–mediated inhibition and restoring antitumor T‑cell activity. • TJ271 – investigational biologic (likely monoclonal antibody), the record does not specify its exact target. Biomarker plans include PD‑L1, CD73, and B7‑H3, and prior B7‑H3–directed therapy was excluded, suggesting a focus on the B7‑H3/CD73 axes, but this is not confirmed. Cells/pathways targeted: • PD‑1/PD‑L1 pathway on T cells and tumor/immune cells to relieve T‑cell exhaustion. • Exploratory focus on B7‑H3 (an inhibitory immune ligand on tumors/vasculature) and CD73 (adenosine-generating enzyme that suppresses immunity) within the tumor microenvironment.